Trading Options with an Edge
Select Page

CRTX

Search by
TICKER SYMBOL

Cortexyme Inc

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology

87.79

-2.63

(-2.909%)

Volume:

536,426

52 week range:

26.66 - 121.98

Market Cap:

2.606B

Company Description:

Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.